Drugs / ATG-019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04281420 | Apr 2020 → Oct 2023 | non-Hodgkin lymphoma | Antengene Therapeutics Limited | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-11 | Antengene Corporation | Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma antengene.com ↗ |
| 2020-04-13 | Antengene Corporation | Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma antengene.com ↗ |
| 2020-01-03 | Antengene Corporation | News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China antengene.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04281420 ↗ |
| Action | Inhibit | “ATG-019, a dual inhibitor of PAK4 and NAMPT” NCT04281420 ↗ |
| Route | Oral | “Oral ATG-019 will be taken three times a week every other day” NCT04281420 ↗ |
| Target | NAMPT | “ATG-019, a dual inhibitor of PAK4 and NAMPT” NCT04281420 ↗ |
| Target | PAK4 | “ATG-019, a dual inhibitor of PAK4 and NAMPT” NCT04281420 ↗ |